-
MRSA Extracellular Vesicles Drive OSCC Proliferation
2026-10-05
A 2026 study identifies methicillin-resistant Staphylococcus aureus extracellular vesicles as active drivers of oral squamous cell carcinoma proliferation, rather than passive markers of infection. The reported mechanism connects EV uptake with ERK/c-Jun signaling, IL-8/CXCR1 activity, and downstream proliferative signaling, while also defining important limits for translating these findings to human cancer biology.
-
Losartan: AT1 Receptor Antagonist Evidence Guide
2026-10-05
Losartan is an angiotensin II receptor antagonist that selectively blocks AT1-receptor signaling, making it relevant to hypertension research and cardiovascular physiology studies. The cited diabetic-nephropathy paper evaluates phillygenin rather than Losartan, so it provides pathway context but does not establish equivalent renal effects for Losartan.
-
Azilsartan and Reactive Astrocyte Research
2026-10-04
Azilsartan (TAK-536) is a pharmacological tool for examining AT1 receptor involvement in renin–angiotensin system signaling. This overview evaluates its relevance to cardiovascular and neuroinflammation research through the 2024 study by Zuo and colleagues, which examined microglia-conditioned astrocyte responses, gastrodin, SIRT3, inflammatory markers, and astrocyte phenotypes. The evidence supports mechanistic investigation, but remains limited to a cell-based model and does not establish therapeutic efficacy or direct clinical relevance.
-
Paclitaxel in Gastric Cancer Assembloid Research
2026-10-03
Paclitaxel and Taxol remain powerful probes of microtubule behavior, but drug response can change when patient-derived tumor cells are studied with matched stromal populations. This article explains how gastric cancer assembloids refine interpretation of paclitaxel response, resistance, and translational relevance.
-
Ziprasidone Targets GOT1 in Pancreatic Cancer
2026-10-02
A 2022 Journal of Molecular Medicine study identified ziprasidone as a non-competitive inhibitor of GOT1, a metabolic enzyme that supports redox balance and proliferation in pancreatic ductal adenocarcinoma. Biochemical, cellular, metabolomic, genetic, and xenograft experiments linked GOT1 inhibition to disrupted glutamine metabolism, oxidative imbalance, reduced migration, and tumor growth suppression.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-10-01
Oliveira and colleagues show that naturally occurring angiotensin fragments can alter SARS-CoV-2 spike-protein binding to host receptors, with the strongest activity observed for selected N-terminally truncated peptides and AXL. The study provides a mechanistic link between renin-angiotensin signaling and viral-entry biology, while its cell-free binding design requires careful validation in cellular and infection models.
-
PDHA1 Succinylation and Macrophage Escape in CCA
2026-10-01
A 2025 Nature Communications study identifies PDHA1 lysine 83 succinylation as a metabolic–immune link in cholangiocarcinoma. The modification increases PDH activity, promotes α-ketoglutarate accumulation, suppresses macrophage MHC-II antigen presentation through OXGR1–MAPK signaling, and may help explain why CPI-613 improves gemcitabine–cisplatin responses in preclinical models.
-
EGFP mRNA m1Ψ for Reporter Delivery
2026-09-30
Use EGFP mRNA m1Ψ as a direct fluorescence benchmark for delivery, translation, and cell-state effects. This workflow adapts dendritic-cell electroporation findings into practical dose, timing, viability, and troubleshooting decisions for reporter studies.
-
Angiotensin II: From Receptor Signal to Translation
2026-09-30
Angiotensin II is more than a vasopressor challenge: it is a controllable mechanistic lever for connecting GPCR signaling, oxidative stress, endothelial dysfunction, vascular smooth muscle cell hypertrophy, and disease-model endpoints. This thought-leadership guide shows translational researchers how to use Angiotensin II strategically, interpret pathway-specific readouts, and design experiments that move beyond routine product-page claims.
-
ALDH2 Activation Delays Pressure-Overload Heart Failure
2026-09-29
A 2025 Experimental Cell Research study identifies ALDH2 activation as a strategy for extending cardiomyocyte proliferation during early postnatal development and delaying pressure overload-induced heart failure in adult mice. Its findings connect aldehyde metabolism and redox control with cardiac cell-cycle regulation, while leaving important questions about mechanism, dosing, and relevance to human disease.
-
Microfluidic Peptide/RNA Complexes for Pulmonary Delivery
2026-09-29
This 2025 study shows that microfluidically prepared complexes of siRNA or mRNA with cationic peptides can be aerosolised using a vibrating mesh nebuliser while retaining RNA binding and in vitro transfection performance. The work provides a practical framework for evaluating formulation robustness under pulmonary delivery stresses, although its evidence remains limited to aerosol and cell-based testing.
-
Targeted Amikacin Delivery into Mycobacterial Granulomas
2026-09-28
Montes-Worboys and colleagues tested whether monocyte-derived dendritic cells could carry active amikacin into Mycobacterium avium granulomas in mice. Their findings support cell-mediated, site-directed drug delivery as a research strategy, while leaving therapeutic efficacy, dosing, and clinical applicability to be established.
-
Streptavidin-FITC for Biotin Detection in LNP Studies
2026-09-27
Use Streptavidin-FITC to visualize biotinylated probes, antibodies, or carefully validated tracer cargo alongside functional lipid nanoparticle (LNP) assays. The workflow connects fluorescence-based localization with recent findings on LNP surface charge and cell V-ATPase activity—while clarifying why a fluorescent signal alone does not prove functional delivery.
-
Sulfaphenazole Restores Vasodilation in Diabetic Mice
2026-09-26
In db/db mice, eight weeks of Sulfaphenazole treatment restored acetylcholine-dependent vasodilation while lowering a plasma oxidative-stress marker and increasing plasma nitrite, without changing glucose levels. The study positions CYP2C inhibition as a candidate mechanism in diabetic vascular dysfunction, while leaving the precise enzyme, tissue-level causal pathway, and relevance to human disease unresolved.
-
Azilsartan (TAK-536) for Reproducible AT1 Studies
2026-09-26
A practical guide to using Azilsartan (TAK-536; SKU B2210) in cell-based AT1 receptor, renin–angiotensin system, and neuroinflammation research. It connects published astrocyte–microglia findings with careful stock preparation, viability-assay controls, data interpretation, and product-selection criteria.